✦ LIBER ✦

238 A randomized, double-blind placebo-controlled study of NV1FGF gene therapy in critical limb ischemia patients (TAMARIS Study): Rationale, design and baseline patient characteristics

✍ Scribed by Eric Van Belle; Sigrid Nikol; Lars Norgren; Iris Baumgartner; Vickie Driver; William Hiatt; Jill Bech

Book ID: 119641521
Publisher: Elsevier
Year: 2011
Tongue: English
Weight: 56 KB
Volume: 3
Category: Article
ISSN: 1878-6480
DOI: 10.1016/s1878-6480(11)70240-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

✍ C. Warren Olanow; Robert A. Hauser; Joseph Jankovic; William Langston; Anthony L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease. Several promising agents in the laboratory have been tested in the clinic, but none has been established in clinical trials to have a disease modifying effect despite positive results becau

Rationale, design, and baseline characte

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure

✍ Fox, Kim; Ford, Ian; Steg, Philippe Gabriel; Tardif, Jean-Claude; Tendera, Micha 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 459 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II—study design and rationale

✍ Rajendra H. Mehta; John H. Alexander; Robert Emery; Stephen J. Ellis; Vic Hassel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Rationale and design of the EMBRACE STEM

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction

✍ Chakrabarti, Anjan K.; Feeney, Kristin; Abueg, Cassandra; Brown, David A.; Czyz, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 322 KB